{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:50:21Z","timestamp":1776174621266,"version":"3.50.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jcyt.2021.12.006","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T07:33:24Z","timestamp":1645256004000},"page":"676-685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hematopoietic stem cell transplantation for uncommon immune-mediated neurological disorders: A literature review"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-9095","authenticated-orcid":false,"given":"Jos\u00e9 Carlos","family":"Jaime-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas D.","family":"Mel\u00e9ndez-Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia M.","family":"Ramos-D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-9760","authenticated-orcid":false,"given":"Mariana","family":"Gonz\u00e1lez-Trevi\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-6427","authenticated-orcid":false,"given":"David","family":"G\u00f3mez-Almaguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2021.12.006_bib0001","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrrheum.2017.7","article-title":"Haematopoietic stem cell transplantation for autoimmune diseases","volume":"13","author":"Swart","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.647425","article-title":"The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-M\u00e9xico Program: A Myriad of Experiences and Knowledge","volume":"12","author":"Murrieta-\u00c1lvarez","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0003","doi-asserted-by":"crossref","first-page":"e1215","DOI":"10.1212\/WNL.0000000000011461","article-title":"Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis","volume":"96","author":"Boffa","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jamaneurol.2020.4025","article-title":"Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis","volume":"78","author":"Miller","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-021-01326-6","article-title":"Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations","author":"Greco","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0006","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","article-title":"Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Acc","volume":"55","author":"Sharrack","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0007","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev-med-070119-115617","article-title":"Hematopoietic Stem Cell Transplantation for Autoimmune Disease","volume":"72","author":"Alexander","year":"2021","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0008","article-title":"Autologous hematopoietic stem cell transplantation for Stiff Person Spectrum Disorder: A clinical trial","author":"Burt","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0009","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1007\/s00415-020-10010-6","article-title":"Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"267","author":"Burt","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp.72.1.127","article-title":"Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy","volume":"72","author":"Vermeulen","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0011","first-page":"1","article-title":"Autologous Hematopoietic Stem Cell Transplantation for Chronic Inflammatory Demyelinating Polyradiculoneuropathy","author":"Masson-Roy","year":"2021","journal-title":"Can J Neurol Sci \/J Can Des Sci Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0012","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s00415-021-10452-6","article-title":"Hematopoietic stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: French experience about four patients, under the behalf of French society for bone marrow transplantation","volume":"268","author":"Urbain","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0013","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/jnnp-2013-306014","article-title":"Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP","volume":"85","author":"Press","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0014","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/jnnp-2017-316271","article-title":"Autologous haematopoietic stem cell transplantation for neurological diseases","volume":"89","author":"Burman","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.it.2005.12.003","article-title":"Renewing the T cell repertoire to arrest autoimmune aggression","volume":"27","author":"Muraro","year":"2006","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0016","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20041679","article-title":"Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients","volume":"201","author":"Muraro","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0017","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/brain\/awh117","article-title":"Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis","volume":"127","author":"Sun","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0018","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ana.23784","article-title":"Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation","volume":"73","author":"Darlington","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0019","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/bmt.2014.277","article-title":"Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients","volume":"50","author":"Arruda","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0020","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14114","article-title":"Early changes in IL-21, IL-22, CCL2, and CCL4 serum cytokines after outpatient autologous transplantation for multiple sclerosis: A proof of concept study","volume":"34","author":"Jaime-P\u00e9rez","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbmt.2008.10.009","article-title":"Late Effects after Autologous Hematopoietic Cell Transplantation","volume":"15","author":"Burns","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0022","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.hemonc.2017.05.009","article-title":"Long-term complications after hematopoietic cell transplantation","volume":"10","author":"Majhail","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0023","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1212\/01.wnl.0000277266.53449.8b","article-title":"Nonmyeloablative Autologous Hematopoietic Stem Cell Transplantation For Refractory CIDP","volume":"69","author":"Oyama","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0024","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1529-8027.2009.00221.x","article-title":"Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy","volume":"14","author":"Mahdi-Rogers","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0025","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/jnnp.2007.128694","article-title":"Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP","volume":"79","author":"Axelson","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0026","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/bmt.2013.18","article-title":"Sj\u00f6gren's syndrome associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treated with autologous and subsequently allogeneic haematopoietic SCT (HSCT)","volume":"48","author":"Bregante","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0027","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1468-1331.2007.01615.x","article-title":"CIDP cured by allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Rem\u00e9nyi","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0028","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/ene.12896","article-title":"Devastating humoral CIDP variant remitted by autologous stem cell transplantation","volume":"23","author":"Scheibe","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0029","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1001\/jamaneurol.2014.1297","article-title":"Autologous Stem Cell Transplantation for Stiff Person Syndrome","volume":"71","author":"Sanders","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/1744666X.2019.1656526","article-title":"The rise of autologous HCT for autoimmune diseases: what is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party","volume":"15","author":"Snowden","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0031","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.bbmt.2017.12.060","article-title":"Autologous Hematopoietic Stem Cell Transplantation May be Highly Effective Treatment for Severe Stiff Person Syndrome","volume":"24","author":"Georges","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0032","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00415-020-10054-8","article-title":"Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience","volume":"268","author":"Kass-Iliyya","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0033","first-page":"26","article-title":"Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Neuromyelitis Optica in Singapore","volume":"27","author":"Koh Yeow","year":"2018","journal-title":"Acta Neurol Taiwan"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102110","article-title":"Allogeneic haematopoietic stem cell transplantation in a refractory case of neuromyelitis optica spectrum disorder","volume":"42","author":"Hau","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102852","article-title":"Autologous hematopoietic stem cell transplantation in a pediatric patient with aquaporin-4 neuromyelitis optica spectrum disorder","volume":"50","author":"Khan","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102990","article-title":"A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder","volume":"53","author":"Burton","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0037","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/acn3.50843","article-title":"T-cell depleted HLA-haploidentical HSCT in a child with neuromyelitis optica","volume":"6","author":"Ceglie","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0038","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458514541978","article-title":"Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party","volume":"21","author":"Greco","year":"2015","journal-title":"Mult Scler J"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0039","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/archneurol.2011.38","article-title":"Failure of Autologous Hematopoietic Stem Cell Transplantation to Prevent Relapse of Neuromyelitis Optica","volume":"68","author":"Matiello","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0040","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jocn.2015.02.007","article-title":"Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant","volume":"22","author":"Aouad","year":"2015","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0041","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/NRL.0b013e3181b126e3","article-title":"A Preliminary Result of Treatment of Neuromyelitis Optica With Autologous Peripheral Hematopoietic Stem Cell Transplantation","volume":"16","author":"Peng","year":"2010","journal-title":"Neurologist"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0042","doi-asserted-by":"crossref","first-page":"e1732","DOI":"10.1212\/WNL.0000000000008394","article-title":"Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica","volume":"93","author":"Burt","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0043","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.24079","article-title":"Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica","volume":"75","author":"Greco","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0044","article-title":"Autologous hematopoietic stem cell transplant in patients with severe refractory neuromyelitis optica spectrum disorder","author":"Brooks","year":"2019","journal-title":"ECTRIMS Online Libr"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00277-010-1071-5","article-title":"Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population","volume":"90","author":"Xu","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0046","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1196\/annals.1444.002","article-title":"Neuromyelitis Optica and Asian Phenotype of Multiple Sclerosis","volume":"1142","author":"Kira","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0047","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.nmd.2016.09.020","article-title":"Successful autologous haematopoietic stem cell transplantation for refractory myasthenia gravis \u2013 a case report","volume":"27","author":"H\u00e5kansson","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0048","doi-asserted-by":"crossref","DOI":"10.1001\/archneurol.2009.28","article-title":"Allogeneic Hematopoietic Cell Transplantation for Refractory Myasthenia Gravis","volume":"66","author":"Strober","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0049","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaneurol.2016.0113","article-title":"Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation","volume":"73","author":"Bryant","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0050","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2018.11.008","article-title":"Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: A case report","volume":"29","author":"Sossa Melo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0051","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41409-020-0810-z","article-title":"Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis","volume":"55","author":"Zhang","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0052","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the Intensity of Conditioning Regimens: Working Definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0053","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0054","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbmt.2009.02.012","article-title":"Defining Conditioning Regimens for BMT\u2014Recognition of \u201cRegimens of Intermediate Intensity","volume":"15","author":"Russell","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0055","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3324\/haematol.2020.268839","article-title":"Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend \u201cwhen and for whom\u201d in 2021?","volume":"106","author":"Gagelmann","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0056","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/annonc\/mdx274","article-title":"Reduced-intensity versus reduced-toxicity myeloablative fludarabine\/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cel","volume":"28","author":"Le Bourgeois","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0057","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2172-13-70","article-title":"Anti-thymocyte globulin (ATG) differentially depletes na\u00efve and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice","volume":"13","author":"Xia","year":"2012","journal-title":"BMC Immunol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0058","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132411","article-title":"Deciphering immune mechanisms in chronic inflammatory demyelinating polyneuropathies","volume":"5","author":"Wolbert","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0059","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2340\/00015555-2046","article-title":"Low-dose Anti-thymocyte Globulin Inhibits Human B-cell Differentiation into Antibody-Secreting Cells","volume":"95","author":"Klaus","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0060","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00652","article-title":"Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System","volume":"8","author":"Pilli","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0062","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.3390\/ijms21155304","article-title":"Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives","volume":"21","author":"Ceglie","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0063","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.msard.2018.12.002","article-title":"Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models","volume":"27","author":"Wu","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/5314541","article-title":"Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications","volume":"2016","author":"Passos","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102843","article-title":"Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis","volume":"50","author":"Wang","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0066","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0067","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.26804","article-title":"Rituximab in refractory chronic inflammatory demyelinating polyneuropathy","volume":"61","author":"Muley","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0068","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/jns.12461","article-title":"Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first-line therapy","volume":"26","author":"Fatehi","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0069","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0070","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1085-9489.2005.0010207.x","article-title":"Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"10","author":"Allen","year":"2005","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0071","article-title":"A HSCT Trial in Stiff Person Syndrome: Limited Benefits Halt Enrollment But Should Be More to Come?","author":"Dalakas","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0072","article-title":"Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis","author":"Burt","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0073","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/art.10495","article-title":"A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis","volume":"46","author":"Moore","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0074","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/1529-0131(200104)44:4<754::AID-ANR131>3.0.CO;2-N","article-title":"High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: Results of an open study to assess feasibility, safety, and efficacy","volume":"44","author":"Verburg","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0075","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/14737175.2020.1820325","article-title":"Autologous hematopoietic stem-cell transplantation in neurological disorders: current approach and future directions","volume":"20","author":"Das","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0076","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41409-021-01277-y","article-title":"New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"56","author":"Burt","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0077","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"Carnero Contentti","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0079","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.645263","article-title":"The Cost Effectiveness of Immunoglobulin vs. Hematopoietic Stem Cell Transplantation for CIDP","volume":"12","author":"Burt","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0080","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0081","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01570","article-title":"Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties","volume":"10","author":"Greco","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2021.12.006_bib0082","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0301-472X(00)00172-7","article-title":"Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis","volume":"28","author":"Slavin","year":"2000","journal-title":"Exp Hematol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324922000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324922000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:46:26Z","timestamp":1761443186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324922000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1465324922000159"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.12.006","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic stem cell transplantation for uncommon immune-mediated neurological disorders: A literature review","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Cell &#38; Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}